GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
47.65
-0.57 (-1.18%)
At close: Jan 20, 2026, 4:00 PM EST
47.74
+0.09 (0.19%)
After-hours: Jan 20, 2026, 7:52 PM EST
GSK Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$630,016
Profits / Employee
$107,608
Market Cap
96.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
| Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
| Dec 31, 2017 | 98,462 | -838 | -0.84% |
| Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
| Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
| Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
| Dec 31, 2013 | 99,451 | -37 | -0.04% |
| Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
| Dec 31, 2011 | 97,389 | 928 | 0.96% |
| Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
| Dec 31, 2009 | 99,913 | 910 | 0.92% |
| Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
| Dec 31, 2007 | 103,483 | 788 | 0.77% |
| Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
| Dec 31, 2005 | 100,728 | 709 | 0.71% |
| Dec 31, 2004 | 100,019 | -900 | -0.89% |
| Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
| Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
| Dec 31, 2001 | 107,470 | -47 | -0.04% |
| Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
| Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
| Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GSK News
- 6 hours ago - Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK - GlobeNewsWire
- 12 hours ago - GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million - Business Wire
- 13 hours ago - GSK to buy food allergy drug maker RAPT in $2.2bn deal - The Guardian
- 16 hours ago - GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug - Market Watch
- 18 hours ago - Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology - PRNewsWire
- 18 hours ago - GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments - WSJ
- 18 hours ago - GSK to buy RAPT Therapeutics for $2.2 billion - Reuters
- 4 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga